# US 7,745,585 B2 · Antibodies to interleukin-like epithelial-mesenchymal transition inducer (ILEI) > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,745,585 B2 - Document ID: US7745585B2 - Status: Granted - Kind: B2 - Application number: 10/570,448 - Filed: 2004-09-02 - Published: 2007-04-19 - Granted: 2010-06-29 - Earliest claimed: 2003-09-02 - Assignees: Boehringer Ingelheim International GmbH - Inventors: Andreas Zophel; Horst Johann Ahorn; Birgit Jung; Renate Konopitzky; Karl-Heinz Heider; Norbert Kraut; Peter Seither; Thomas Waerner; Hartmut Beug; Martin Jechlinger; Ido M. Tamir; Andreas Weith; Stefan Gruenert - Web page: https://patentgrep.com/patent/US7745585B2 ## CPC - C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones} - A61P 11/00: Drugs for disorders of the respiratory system - A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like - A61P 35/00: Antineoplastic agents - A61P 35/04: specific for metastasis - C07K 14/52: Cytokines; Lymphokines; Interferons - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The functional characterization of ILEI to be a novel cytokine involved in epithelial/mesenchymal transition and the identification of biologically active ILEI provides the basis for generating ILEI inhibitors, in particular anti-ILEI antibodies, that are useful in the therapy of cancer, fibrosis and COPD. ## Claims ### Claim 1 An antibody or an antibody fragment which binds to a polypeptide which consists of the sequence set forth in SEQ ID NO: 10. ### Claim 2 An antibody or an antibody fragment which binds to a polypeptide which consists of amino acids 189 to 211 of SEQ ID NO: 2 or SEQ ID NO: 4. ### Claim 3 (depends on 1) The antibody or the antibody fragment of claim 1, which is a polyclonal antibody. ### Claim 4 (depends on 1) The antibody of claim 1 or fragment thereof, which specifically binds to human ILEI (Interleukin-like EMT inducer). ### Claim 5 (depends on 1) The antibody or fragment thereof according to claim 1, which is a monoclonal antibody. ### Claim 6 (depends on 5) The antibody or fragment thereof of claim 5, which is a recombinant antibody. ### Claim 7 (depends on 1) The antibody or fragment thereof of claim 1, which is chimeric. ### Claim 8 (depends on 1) The antibody or fragment thereof of claim 1, which is humanized. ### Claim 9 (depends on 1) The antibody or fragment thereof according to claim 1, which is human. ### Claim 10 (depends on 1) The antibody fragment according to claim 1, which is a Fab fragment. ### Claim 11 (depends on 1) The antibody or fragment thereof of claim 1, which is conjugated to a therapeutic moiety or a radioactive metal ion. ### Claim 12 (depends on 1) A pharmaceutical composition comprising, as an active ingredient, an antibody or a fragment according to claim 1 and a pharmaceutically acceptable carrier. ### Claim 13 (depends on 2) The antibody or the antibody fragment of claim 2, which is a polyclonal antibody. ### Claim 14 (depends on 2) The antibody of claim 2 or fragment thereof, which specifically binds to human ILEI. ### Claim 15 (depends on 2) The antibody or fragment thereof according to claim 2, which is a monoclonal antibody. ### Claim 16 (depends on 15) The antibody or fragment thereof of claim 15, which is a recombinant antibody. ### Claim 17 (depends on 2) The antibody or fragment thereof of claim 2, which is chimeric. ### Claim 18 (depends on 2) The antibody or fragment thereof of claim 2, which is humanized. ### Claim 19 (depends on 2) The antibody or fragment thereof according to claim 2, which is human. ### Claim 20 (depends on 2) The antibody fragment according to claim 2, which is a Fab fragment. ### Claim 21 (depends on 2) The antibody or fragment thereof of claim 2, which is conjugated to a therapeutic moiety or a radioactive metal ion. ### Claim 22 (depends on 2) A pharmaceutical composition comprising, as an active ingredient, an antibody or a fragment according to claim 2 and a pharmaceutically acceptable carrier.